Major win for the chordoma community today: as part of our TBXT Challenge, @XChemInc discovered a compound that binds to brachyury—chordoma's key vulnerability—with much greater affinity than any previously published. In doing so, they've overcome a longstanding scientific hurdle, and the achievement could open the door to developing several types of promising drugs aimed at this target.
More: https://t.co/sxzHD5Q0aU
Very grateful to all of our supporters, incl. @biohub and @TheMarkFdn, for making this possible. Excited to see what comes next, including more discoveries from our ongoing Challenge!
Our scientists in @CFLabsResearch are continuously learning more about how to attack chordoma. These latest findings bring us another step forward in our search for better treatments:
We're excited to share new results that strengthen and refine the rationale for targeting TBXT (brachyury) in chordoma via transcriptional inhibition.
Previous studies showed that transcriptional CDK inhibitors, such as THZ1 and dinaciclib, reduce chordoma cell viability and downregulate TBXT expression, potentially through disruption of super-enhancer-associated transcription [1–4]. However, because these compounds inhibit multiple transcriptional CDKs, it remained unclear exactly which CDK(s) are responsible for these effects.
The recent development of more selective transcriptional CDK inhibitors provides an opportunity to answer this question.
With the goal of facilitating clinical translation of transcriptional CDK inhibitors, we evaluated the effect of selective inhibitors of CDK7 (samuraciclib and SY-5609), CDK9 (atuveciclib and KB-0742), and CDK12/13 (THZ-531 and SR-4835) on chordoma cell viability and TBXT transcription.
First, we confirmed previous findings that multi-CDK inhibitors THZ1 and dinaciclib suppress TBXT expression.
But we were intrigued to find that among the more selective inhibitors we tested, only CDK12/13 inhibitors substantially reduced TBXT expression.
The strongest effect was observed for SR-4835, which also promotes cyclin K degradation, thereby enhancing the suppression of CDK12/13 signaling. Chordoma cells were also significantly more sensitive to selective CDK12/13 inhibitors than to selective CDK7 and CDK9 inhibitors: https://t.co/rDLvI7E46O
We then tested SR-4835 across a larger panel of 10 chordoma cell lines and found that it consistently reduced cell viability, with EC50s ranging from 28 to 719 nM, and at 500 nM significantly reduced TBXT expression in all cell lines: https://t.co/f0xZRBXks6
These findings are particularly interesting in light of previous evidence that CDK12 is highly expressed in some chordomas, with higher expression associated with recurrent or metastatic disease and poorer survival [5].
Together, these results strengthen the case for investigating CDK12/13 and cyclin K as therapeutic targets in chordoma, including as a means of indirectly suppressing TBXT expression.
We're grateful to the investigators whose work laid the foundation for these studies, and most importantly to the patients and many donors who made this work possible!
This is a really smart idea. A lot of useful scientific outputs never see the light of day because there’s insufficient incentive to take the time to share them. The duplication of effort and missed opportunities to enable subsequent work are hard to quantify but are surely massive. I wonder how much more scientific progress could be unlocked if some modest funding was provided at the end of every grant to ensure all useful outputs are shared. Maybe something we will try at @ChordomaFDN
Chordoma researchers: @BenjaminGVincen has shared predicted brachyury (TBXT) epitopes, which could help inform immunotherapy development: https://t.co/ynT0HdD0fI
If you're interested in advancing research like this, we encourage you to explore ASPIRE, our new funding opportunity with @TheMarkFdn for chordoma surface-target research: https://t.co/967Em6sGoF
New blog post on an excursion into potential brachyury-derived epitopes in chordoma; many thanks to @ChrisHeery for the discussion that prompted this.
https://t.co/5V92r0xUn2
Today @GarySinise is honoring the extraordinary life of his son, Mac, with the release of a new book: Graceful Warrior. Throughout his journey with chordoma, Mac showed remarkable perseverance, continuing to create music, find joy, and make a difference for others even as his illness progressed.
We’re grateful to Gary for sharing Mac’s story, and for reminding us of the importance of carrying each other through life's most difficult moments. We encourage everyone to pick up a copy of this deeply meaningful book.
Well, folks, today would have been my son Mac’s 36th birthday.
It felt fitting to release Graceful Warrior today, on his birthday. This book tells the story of our family’s journey through some of life’s most difficult moments, and the faith, hope, and love that carried us through. My hope is that somewhere in these pages, someone facing their own difficult season might find a little encouragement, strength, or comfort. If this book can help even one person, then sharing our story will have been worth it.
Thank you to everyone who preordered the book, shared kind words, and supported me throughout this journey. It means more than I can say.
Graceful Warrior is available now wherever books are sold. I hope you’ll pick up a copy. And the audio book is available also. I recorded it this past summer.
Happy birthday, Mac. We love you and miss you every day.
Graceful Warrior here and other online outlets: https://t.co/WgtmSo5HTE
Planning to apply for the TBXT and Beyond ASPIRE Awards? Join The Mark Foundation and @ChordomaFDN for an informational webinar this Thursday, Nov. 12 at 11 a.m. EST.
Link to register: https://t.co/4IH5Nx1UUq
Leaving #SITC26 with new research ideas? 💡
Several CRI grants, ranging from $300K to $1M, have deadlines coming up, starting Nov. 15.
Explore funding opportunities and apply: https://t.co/cxfGEnHEp3
#CancerImmunotherapy@sitcancer
Thinking about applying for a TBXT and Beyond ASPIRE Award?
With our partners at the @ChordomaFDN, we are hosting an informal informational webinar on Nov. 12 to share more details about this grant opportunity focused on expanding the chordoma surfaceome. Register now: https://t.co/4rKl2g6YQP
🚨Now accepting grant proposals!🚨
In partnership with @chordomafdn, we are launching the TBXT and Beyond ASPIRE Awards to accelerate novel therapeutic strategies targeting the chordoma surfaceome.
💵 Up to $500K over 24 months
🗓️ LOIs due: Dec 10
https://t.co/0qINfu31ze
🧵👇
Our latest newsletter includes encouraging clinical trial results, new research funding, job openings, and more! We hope you'll check it out, and you can sign up at https://t.co/ywcnNUv0he to get the next one in your inbox.
October's edition here: https://t.co/bdQe9b9tGg
We’re thrilled to announce a new joint grants program with @TheMarkFdn offering awards of up to $500K to help pave the way for chordoma patients to benefit from emerging treatment approaches that target cell surface proteins or peptides presented by MHC molecules on cancer cells. This is a major area of opportunity that builds on the results of several projects we’ve supported in recent years to identify surface targets.
Researchers: the request for proposals will open on Monday, October 26. More info: https://t.co/JTfflMGCjs
We're expanding our team to serve a growing number of researchers and companies making progress towards the first brachyury/TBXT drugs. If being a crucial part of drugging this once undruggable target would be fulfilling for you or someone you know we'd love to talk!
We're hiring a Senior Research Associate to join our @CFLabsResearch team and support the development of first-in-class drugs targeting brachyury (TBXT), a critical vulnerability in chordoma. Help us build on exciting recent advances in drugging this promising target! More: https://t.co/K8StAejYOP
A clinical trial we're supporting that combines two drugs, pemetrexed and pembrolizumab, is yielding encouraging early results: tumors have shown response in most chordoma patients treated so far.
The trial is still enrolling adults with progressive chordoma at Saint John's Cancer Institute in California. Our Clinical Trial Assistance Program can help ease the financial burden of participation, providing eligible patients with up to $1,000 per month toward travel-related expenses.
Learn more: https://t.co/QrGP1CAoSB
We're hiring! Seeking a Major Gift Officer with deep individual-giving experience, a track record of increasing year-over-year revenue from their personal portfolio, and a love of meeting donors face to face—all in service of progress for people affected by chordoma.
Learn more: https://t.co/K8StAejYOP
At our recent International Research Workshop and Community Conference, researchers, clinicians, patients, and families came together to advance a shared goal: improving outcomes for everyone affected by chordoma. From promising clinical trial results to momentum in new drug discovery and advances in patient care, we're seeing the impact of years of collective effort, with even more possibilities ahead.
Read the highlights: https://t.co/IJvnxwWTbe
Many thanks to our event sponsors: @MassGeneralBrigham Cancer Institute, @BrownUniversity Neurosurgery Foundation, @CedarsSinai, @icotecmed, @NorthwellHealth, @nyulangone , and @PennMedicine Radiation Oncology.
Our Patient Navigation Service is getting stronger.
As chordoma care options have expanded considerably, treatment decisions have also become more complex.
With the addition of our first Nurse Navigator, we can now provide more in-depth, clinically informed support to patients and loved ones, helping them access the right expertise and options and ultimately receive the best possible care.
Learn more about how we’re expanding our free Patient Navigation service to meet the changing needs of our community: https://t.co/pjRHbeKX4G
X-Chem is the first team to win a prize in the Chordoma Foundation’s TBXT Challenge, with a binding hit verified by the foundation’s lab. Could other rare-disease foundations use the same model? https://t.co/r1rOD9WBTG
Mac Sinise faced chordoma with extraordinary courage. We're glad @GarySinise will be sharing his son's story in this new book so that more people can come to know Mac. And we're grateful to Gary and to everyone who continues to fight alongside us for better outcomes for all those facing this disease.
I’d like you to know that I am releasing my second book, Graceful Warrior: The True Story of a Son, a Father, and a Family Who Carried Each Other Through, on November 10- my son Mac's birthday. This project has been two years in the making and it is more deeply personal than anything I have ever done. I wrote this book not only to honor my son, but also to offer hope, strength, and comfort to others who are currently walking through their own challenging valleys.
I wanted to take a moment and share a little more about Mac - a snippet of what you'll hear more about in the book.
Mac was vibrant. He was a talented musician and composer, a proud uncle, and a loving son and brother. At 27, he was diagnosed with chordoma, a rare form of bone cancer. Mac never let this slow him down. He pushed forward, serving through the Gary Sinise Foundation until he needed to step back to focus on the fight. But even in that, he fully embraced every moment he could, writing, composing, and recording music for his album Resurrection and Revival,
I look forward to sharing more about Mac, my family's journey, and the love and faith that carried us through in the coming weeks. And my heart goes out to anyone struggling with a similar challenge. If you’d like to pre-order the book, you can do so through Barnes & Nobles, Amazon, or Premier Collectibles.